Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.